ACHL
Achilles Therapeutics PLC ADR
NASDAQ: ACHL · HEALTHCARE · BIOTECHNOLOGY
$1.48
+0.00% today
Updated 2026-04-29
Market cap
$63.22M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-1.66
Dividend yield
—
52W range
$0 – $0
Volume
1.2M
WallStSmart proprietary scores
32
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C5.0
Quality
C+3.0
Profitability
D5.0
Valuation
C+—/9
Piotroski F-Score
—
—
Altman Z-Score
—
—
Industry rank
—
View all highly rated stocks (75+) →201 stocks currently score above 75
Price targets
Analyst target
$0.50
-66.22%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
Price chart
X-Ray snapshot
Strengths
Insufficient data
Risks
- Thin margins at 0.00%
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2020 | 2021 | 2022 | 2023 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $-33.20M | $-61.10M | $-71.18M | $-69.67M | $-19.59M |
| EPS | — | — | — | — | $-1.66 |
| Free cash flow | $-37.10M | $-66.92M | $-67.05M | $-49.55M | — |
| Profit margin | — | — | — | — | — |
Peer comparison
Smart narrative
Achilles Therapeutics PLC ADR trades at $1.48. Our Smart Value Score of 32/100 indicates the stock is weak.
Frequently asked questions
What is Achilles Therapeutics PLC ADR's stock price?
Achilles Therapeutics PLC ADR (ACHL) trades at $1.48.
Is Achilles Therapeutics PLC ADR overvalued?
Smart Value Score 32/100 (Grade F, Strong Sell).
What is the price target of Achilles Therapeutics PLC ADR (ACHL)?
The analyst target price is $0.50, representing -66.2% downside from the current price of $1.48.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio—
ROE-52.10%
Beta1.25
50D MA$1.32
200D MA$1.03
Shares out0.04B
Float0.02B
Short ratio—
Avg volume1.2M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—